According to a report ,“Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis Report By Drug Type (Stimulant, Non-stimulant), By Demographic, By Distribution Channel (Hospital & Retail Pharmacy), And Segment Forecasts, 2019 – 2025” , published by Grand View Research, Inc., The global attention deficit hyperactivity disorder market size is expected to reach USD 24.9 billion by 2025, exhibiting a 6.4% CAGR during the forecast period. Increase in awareness regarding ADHD among patients, physicians, and other healthcare providers is likely to up demand for effective treatment, in turn, propelling market growth.
Key Takeaways from the report:
Increasing access to health insurance for mental health treatment and rising incidence of ADHD are expected to propel market growth in the coming years
By drug type, the stimulant drugs segment accounted for the largest share in the market in 2018 and is anticipated to maintain its dominance during the forecast period. This can be attributed to effectiveness of drugs in treating of ADHD symptoms and commercialization of new drugs
Based on demographics, adults held the maximum share in the ADHD market in 2018 due to high prevalence of the condition across the globe, increased awareness about mental health, and launch of effective drugs with minimum adverse effects
By distribution channel, retail pharmacy accounted for the largest share in 2018 due to increasing number of prescriptions. This can be attributed to rise in patient care initiatives by retail pharmacies
Geographically, North America dominated the global ADHD market in 2018 owing to high awareness of mental health, increasing patient population, and local presence of market players
Asia Pacific is anticipated to observe significant growth during the forecast period owing to government initiatives to provide effective treatment for ADHD and rising patient population due to stressful lifestyle
Some of the key players in the market are Eli Lily & Company; Pfizer; Johnson & Johnson Services, LLC; Lupin; Shire; Mallinckrodt; Prude Pharma L.P.; and NEOS Therapeutics Inc.
Browse More Reports in Pharmaceuticals Industry:
Furthermore, there has been a steady rise in ADHD patients during the last 20 years. According to a study conducted by the National Health Interview Survey, the prevalence of ADHD among children and adolescents in U.S. rose from 6.1% in 1997-1998 to 10.2% in 2015-2016.
Approval and commercialization of drugs, increase in number of clinical trials, and rise in awareness regarding diagnosis and treatment of the condition is expected to boost market growth over the forecast period.
Grand View Research has segmented the global ADHD market by drug type, demographic, distribution channel, and region:
ADHD Drug Outlook (Market Revenue in USD Million, 2014 – 2025)
Amphetamine
Methylphenidate
Lisdexamfetamine
Dexmethylphenidate
Atomoxetine
Guanfacine
Clonidine
ADHD Drug Type Outlook (Market Revenue in USD Million, 2014 – 2025)
Stimulant
Non-stimulant
ADHD Demographic Outlook (Market Revenue in USD Million, 2014-2025)
Adult (Aged 18 and above)
Children
ADHD Distribution Channel Outlook (Market Revenue in USD Million, 2014-2025)
Retail Pharmacy
Hospital Pharmacy
ADHD Regional Outlook (Market Revenue in USD Million, 2014 – 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Asia Pacific
China
Japan
Latin America
Brazil
Mexico
Middle East and Africa
South Africa
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grad View Research, Inc.
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com/
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:201, Spear Street, 1100 City: San FranciscoState: CaliforniaCountry: SwitzerlandWebsite: www.grandviewresearch.com/industry-analysis/attention-deficit-hyperactivity-disorder-adhd-market